Growth Metrics

Corcept Therapeutics (CORT) Change in Cash (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Change in Cash for 15 consecutive years, with -$11.8 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Cash rose 68.93% year-over-year to -$11.8 million; the TTM value through Mar 2026 reached $18.9 million, up 131.57%, while the annual FY2025 figure was -$7.2 million, 9.08% up from the prior year.
  • Change in Cash hit -$11.8 million in Q1 2026 for Corcept Therapeutics, down from -$4.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $233.6 million in Q1 2023 and bottomed at -$127.6 million in Q2 2023.
  • Average Change in Cash over 5 years is $1.8 million, with a median of -$4.6 million recorded in 2025.
  • Year-over-year, Change in Cash surged 2107.68% in 2022 and then plummeted 506.64% in 2023.
  • Corcept Therapeutics' Change in Cash stood at $16.1 million in 2022, then skyrocketed by 47.65% to $23.8 million in 2023, then crashed by 140.52% to -$9.6 million in 2024, then skyrocketed by 51.76% to -$4.6 million in 2025, then plummeted by 153.22% to -$11.8 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$11.8 million, -$4.6 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.